No profile data available.
Fulcrum Therapeutics, Inc. (FULC) is a healthcare company in the brain and nerve treatment drugs industry, based in Cambridge, United States, with about 9 full-time employees.
It reported revenue of $0 for fiscal year 2025, down 100.0% from fiscal year 2024, and net income of -$74.88 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $287.64 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Fulcrum Therapeutics reported $0 in revenue for fiscal year 2025, down 100.0% from $80.00 million in fiscal year 2024. In Q1 2026 revenue was $0.
$287.64 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Prothena Corporation plc (PRTA), Relmada Therapeutics, Inc. (RLMD), Benitec Biopharma Inc. (BNTC), Larimar Therapeutics, Inc. (LRMR).